Journal of Biosciences and Medicines,
Journal Year:
2023,
Volume and Issue:
11(08), P. 192 - 207
Published: Jan. 1, 2023
Glioblastoma
Multiforme
(GBM)
represents
one
of
the
most
aggressive
and
metastatic
brain
tumors,
with
a
dismal
success
rate
less
than
three
percent
after
five
years,
particularly
in
tumors
active
immune
checkpoints.
This
necessitates
development
targeted
endogenous
agents
for
precise
GBM
treatment.
Previous
experiments
utilizing
Chemovar
Specific
Cannabis
Extractions
(CSCEs),
fractionated
polar
solvents
quantified
using
Liquid
Gas
Column
Chromatography
combined
Mass
Spectrometry
(LC/GCMS),
have
shown
reduced
viability
motility
human
cell
lines.
However,
complexity
botanical
substance
has
hindered
personalization
standard
cannabis
medicines
due
to
unknown
synergistic
effects
multiple
compounds.
To
address
this
limitation,
our
study
focuses
on
exposing
AM251
cells
chemovar
fractions
extracted
non-polar
solvent,
thereby
isolating
broader
spectrum
constituents.
By
employing
LC/GCMS
conjunction
Nuclear
Magnetic
Resonance
(NMR),
we
identified
nine*
compounds
present
CSCE
that
exhibit
significant
efficacy
(0.1
μM)
inducing
cytotoxicity*
tumor
cells.
Conversely,
fraction
experiment
did
not
demonstrate
against
UM251
The
quantification
individual
within
extraction
selectively
induces
death
holds
promise
guiding
future
research
facilitating
standardized
therapy.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 5, 2025
Cannabinoids
relieve
pain,
nausea,
anorexia
and
anxiety,
improve
quality
of
life
in
several
cancer
patients.
The
immunotherapy
with
checkpoint
inhibitors
(ICIs),
although
very
successful
a
subset
patients,
is
accompanied
by
moderate
to
severe
immune-related
adverse
events
(ir-AE)
that
often
necessitate
its
discontinuation.
Because
their
role
symptomatic
relief,
cannabinoids
have
been
used
combination
immune
inhibitor
(ICI)
immunotherapy.
A
few
studies
strongly
suggest
the
use
medicinal
cannabis
patients
attenuates
many
ir-AE
associated
ICI
increase
tolerability.
However,
no
significant
beneficial
effects
on
overall
survival,
progression
free
survival
or
relapses
were
observed;
rather,
some
noted
concurrent
administration
clinical
benefits
latter.
cannabinoids'
well
documented
immunosuppressive
mediated
through
cannabinoid
recptor-2
(CB2),
we
propose
considering
this
receptor
as
an
inhibitory
per
se.
simultaneous
neutralization
CB2,
treatment,
may
lead
better
outcomes
receiving
In
regard,
such
cannabidiol
(CBD)
cannabigerol
(CBG),
little
agonism
for
be
therapeutic
choices.
Additional
strategies
e.g.,
monoacylglycerol
lipase
(MAGL)
degrade
endocannabinoids
lipogenesis
formation
lipid
bilayers
cells
also
explored.
Future
should
take
into
consideration
gut
microbiota,
CYP450
polymorphism
haplotypes,
cannabinoid-drug
interactions
genetic
somatic
variations
occurring
receptors
signaling
pathways
personalized
cannabis-based
therapies
ICIs.
This
rational
knowledge-based
regimens
tailored
individual
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(3), P. 2721 - 2721
Published: Feb. 1, 2023
Increasing
evidence
supports
the
therapeutic
potential
of
rare
cannabis-derived
phytocannabinoids
(pCBs)
in
skin
disorders
such
as
atopic
dermatitis,
psoriasis,
pruritus,
and
acne.
However,
molecular
mechanisms
biological
action
these
pCBs
remain
poorly
investigated.
In
this
study,
an
experimental
model
inflamed
human
keratinocytes
(HaCaT
cells)
was
set
up
by
using
lipopolysaccharide
(LPS)
order
to
investigate
anti-inflammatory
effects
cannabigerol
(CBG),
cannabichromene
(CBC),
Δ9-tetrahydrocannabivarin
(THCV)
cannabigerolic
acid
(CBGA).
To
aim,
pro-inflammatory
interleukins
(IL)-1β,
IL-8,
IL-12,
IL-31,
tumor
necrosis
factor
(TNF-β)
IL-10
levels
were
measured
through
ELISA
quantification.
addition,
IL-12
IL-31
after
treatment
HaCaT
cells
with
THCV
CBGA
presence
selected
modulators
endocannabinoid
(eCB)
signaling.
latter
cells,
activation
17
distinct
proteins
along
mitogen-activated
protein
kinase
(MAPK)
pathway
also
investigated
via
Human
Phosphorylation
Array.
Our
results
demonstrate
that
significantly
blocked
inflammation
reducing
release
all
ILs
tested,
except
for
TNF-β.
Moreover,
reduction
expression
reverted
blocking
eCB-binding
TRPV1
receptor
inhibiting
eCB-hydrolase
MAGL.
Remarkably,
modulated
phosphorylated
forms
(and
hence
activity)
MAPK-related
GSK3β,
MEK1,
MKK6
CREB
engaging
eCB
hydrolases
MAGL
FAAH.
Taken
together,
ability
exert
effect
modifications
MAPK
signaling
opens
new
perspectives
inflammation-related
pathologies.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: Feb. 11, 2025
Vanilloid1
(TRPV1),
a
subfamily
of
transient
receptor
channels,
is
one
the
non-selective
calcium
which
bridge
between
cellular
response
and
extracellular
environmental
networks,
involved
in
variety
pathophysiological
processes.
It
also
process
cancer
occurrence
progression,
researchers
are
revealing
its
role
cancer.
In
this
paper,
we
review
expression
significance
TRPV1
various
cell
types,
apoptosis-proliferation
balance,
invasion
metastasis,
tumor
micro-environment,
with
emphasis
on
mechanisms
by
mediates
inflammatory
response,
immune
system,
thus
regulates
We
discussed
latest
directions
current
challenges
receptor-targeting
therapy
for
cancer,
summarized
odorous
traditional
herbs
that
modulate
receptors,
view
to
developing
anti-tumor
drugs
targeting
receptors
future.
Cellular and Molecular Life Sciences,
Journal Year:
2023,
Volume and Issue:
80(9)
Published: Aug. 29, 2023
We
previously
reported
that
TRPM7
regulates
glioma
cells'
stemness
through
STAT3.
In
addition,
we
demonstrated
FOSL1
is
a
response
gene
for
TRPM7,
and
the
serves
as
an
oncogene
to
promote
proliferation
invasion.In
present
study,
determined
effects
of
on
stem
cell
(GSC)
markers
CD133
ALDH1
by
flow
cytometry,
maintenance
activity
extreme
limiting
dilution
assays
(ELDA).
To
further
gain
insight
into
mechanism
which
activates
transcription
contribute
stemness,
constructed
promoter
its
GAS
mutants
followed
luciferase
reporter
ChIP-qPCR
in
line
patient-derived
xenoline.
examined
GSC
well
immunohistochemistry
staining
(IHC)
brain
tissue
microarray
(TMA)
patients.We
revealed
knockdown
reduces
expression
ALDH1,
required
maintain
cells.
The
experiments
also
showed
mutations
-
328
336
378
386
elements
markedly
reduced
activity.
Constitutively
active
STAT3
increased
while
dominant-negative
decreased
Furthermore,
overexpression
enhanced
silencing
STAT3,
nuclear
lysates
cells
stimulated
constitutively
activated
can
bind
two
elements,
respectively.
deacetylation
at
Lys-116
residue
located
within
DNA
binding
domain
led
increase
transcriptional
found
protein
associated
with
grades
malignant
glioma,
correlates
patients.These
combined
results
induced
activation,
mediated
action
shown
be
important
stemness.
These
indicated
FOSL1,
similar
diagnostic
marker
potential
drug
target
patients.
Frontiers in Cellular Neuroscience,
Journal Year:
2023,
Volume and Issue:
17
Published: Dec. 21, 2023
Glioblastoma
(GB)
is
a
highly
malignant
primary
brain
tumor
with
limited
treatment
options
and
poor
prognosis.
Despite
current
approaches,
including
surgical
resection,
radiation
therapy,
chemotherapy
temozolomide
(TMZ),
GB
remains
mostly
incurable
due
to
its
invasive
growth
pattern,
drug
penetration
beyond
the
blood-brain
barrier
(BBB),
resistance
conventional
therapies.
One
of
main
challenges
in
effectively
eliminating
infiltrating
cancer
cells
that
remain
parenchyma
after
resection.
We’ve
reviewed
most
recent
surveyed
potential
strategies
aimed
at
enhancing
local
outcomes.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(9), P. 1245 - 1245
Published: Sept. 21, 2024
Background:
Breast
cancer
therapy
has
been
facing
remarkable
changes.
Classic
treatments
are
now
combined
with
other
therapies
to
improve
efficacy
and
surpass
resistance.
Indeed,
the
emergence
of
resistance
demands
development
novel
therapeutic
approaches.
Due
key
estrogen
signaling,
receptor-positive
(ER+)
breast
treatment
always
focused
on
aromatase
inhibition
ER
modulation.
Lately,
effects
phytocannabinoids,
mainly
Δ9-tetrahydrocannabinol
(THC)
cannabidiol
(CBD),
have
evaluated
in
different
cancers,
including
breast.
However,
Cannabis
sativa
contains
more
than
120
phytocannabinoids
less
researched
understood.
Methods:
Here,
we
evaluated,
both
silico
vitro,
ability
129
modulate
important
molecular
targets
ER+
cancer:
aromatase,
ER,
androgen
receptor
(AR).
Results:
In
results
suggested
that
some
cannabinoids
may
inhibit
act
as
ERα
antagonists.
Nine
selected
showed,
potential
either
antagonists
inverse
agonist
properties,
or
agonists.
Moreover,
these
were
considered
weak
inhibitors
AR
action.
Conclusions:
Overall,
present,
for
first
time,
a
comprehensive
analysis
actions
tumors,
pointing
out
their
diseases.
Molecules,
Journal Year:
2024,
Volume and Issue:
29(7), P. 1682 - 1682
Published: April 8, 2024
Phytocompounds
have
been
evaluated
for
their
anti-glioblastoma
actions
decades,
with
promising
results
from
preclinical
studies
but
only
limited
translation
into
clinics.
Indeed,
by
targeting
multiple
signaling
pathways
deregulated
in
cancer,
they
often
show
high
efficacy
the
vitro
studies,
poor
bioavailability,
low
tumor
accumulation,
and
rapid
clearance
compromise
vivo.
Here,
we
present
new
avenues
phytocompound
research
improvement
of
glioblastoma
therapy,
including
ways
to
enhance
response
temozolomide
using
phytochemicals,
current
focus
on
phytocompound-based
immunotherapy,
or
use
phytocompounds
as
photosensitizers
photodynamic
therapy.
Moreover,
new,
intensively
approaches,
such
chemical
modifications
phytochemicals
encapsulation
numerous
types
nanoformulations,
improve
bioavailability
delivery
brain.
Finally,
clinical
trials
evaluating
role
phytocompound-derived
drugs
therapy
less
studied
plant
extracts
that
recently
found
possess
properties.
Overall,
recent
advancements
are
encouraging;
however,
more
3D
models,
vivo
it
is
possible
upgrade
treatment
a
satisfactory
level.